The UK’s GlaxoSmithKline and Germany’s CureVac are to develop a new generation of mRNA Covid-19 vaccines to tackle emerging variants that have shown some resistance to current vaccines.
The two companies plan to work on a joint approach to address “multiple emerging variants” in one jab, they said in a statement on Wednesday. The deal is worth €150m, the companies said.
GSK will also help to make up to 100m doses of CureVac’s vaccine candidate through its manufacturing facilities in Belgium. CureVac’s vaccine is going through the final phases of testing.
您已閱讀71%（558字），剩餘29%（232字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。